Drug · CHEMBL446452
ARUNDINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ARUNDINE. Drugs and targets, record CHEMBL446452. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL446452
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- 1,1-bis(3'-indolyl)methane, 3,3'-diindolylmethane, 3,3-diindolylmethane, Diindolylmethane
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases5
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| prostate cancer | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0008315 |
| cervical intraepithelial neoplasia | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0022394 |
| breast cancer | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| prostate adenocarcinoma | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005082 |
| systemic lupus erythematosus | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0007915 |
Source Open Targets
Trials10
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00888654 | Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy | Phase 2 | 41 | 2015-03-30 | diindolylmethane | Its name | ClinicalTrials.gov |
| NCT03802721 | Pharmacokinetics of Benzo[a]Pyrene: Impact of Diet | Early phase 1 | 7 | 2025-05-09 | diindolylmethane | Its name | ClinicalTrials.gov |
| NCT00462813 | Diindolylmethane in Treating Patients With Abnormal Cervical Cells | Phase 3 | 3,000 | diindolylmethane | Its name | ClinicalTrials.gov | |
| NCT00212381 | Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia | Phase 3 | 62 | diindolylmethane | Its name | ClinicalTrials.gov | |
| NCT00450229 | Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer | Phase 1 | 45 | diindolylmethane | Its name | ClinicalTrials.gov | |
| NCT00784394 | Diindolylmethane in Preventing Cancer in Healthy Volunteers | Phase 1 | 20 | diindolylmethane | Its name | ClinicalTrials.gov | |
| NCT00392652 | Diindolylmethane in Healthy Volunteers | Phase 1 | 14 | diindolylmethane | Its name | ClinicalTrials.gov | |
| NCT00305747 | Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy | Phase 1 | 12 | diindolylmethane | Its name | ClinicalTrials.gov | |
| NCT02483624 | 3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus | Phase 1 | 6 | 3,3'-diindolylmethane | Its name | ClinicalTrials.gov | |
| NCT01612910 | Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery | Phase 2 | 0 | diindolylmethane | Its name | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials1
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 19939441 | RESULT | 1 |
Source PubMed
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL446452
GET https://conductscience.org/api/drugs/v1/CHEMBL446452/targets